Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Litx (talaporfin sodium + interstitial LED) vs standard of care in unresectable hepatocellular carcinoma
2007-004795-39Phase 3Completed
- Sponsor
- Light Science Oncology
- Start
- Mar 2008
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of talaporfin sodium in hepatocellular carcinoma (HCC) (2 arms), sponsored by Light Science Oncology. Primary endpoint: Overall survival. Started Mar 2008; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2007-004795-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004795-39.